This book comprehensively reviews the recent progress in their pathogenesis and management approaches for neurological disorders. It focuses on understanding the molecular mechanism, pathology, novel nanotechnology-based approaches against stroke, Alzheimer’s disease, Parkinson disease, Huntington’s disease, Multiple sclerosis, and Epilepsy. The book provides the basic understanding about the development and progression of these diseases, and recent pharmacotherapeutic approaches for their management. It also discusses challenges in drug development for neurological disorders, including preclinical models of disorders, the need for drugs to cross the blood-brain-barrier, and limited understanding of relevant pathophysiology. The book also focuses on different conventional and novel strategies for drug delivery in neurological disorders. Towards the end, the book reviews the applications of nanotechnology for the diagnosis of neurological disorders. One of the chapters is focused on the role of herbal actives in the treatment of neurological disorders. Finally, a chapter is included on nanotechnology-based approaches for diagnosis of neurological disorders. This book is a useful resource for students and researchers of pharmaceutical sciences, life sciences, material sciences, and nanosciences.

The development of innovative drugs is becoming more difficult while relying on empirical approaches. This inspired all major pharmaceutical companies to pursue alternative model-based paradigms. The key question is: How to find innovative compounds and, subsequently, appropriate dosage regimens?

This introductory text explains both the basic science and the applications of biotechnology-derived pharmaceuticals, with special emphasis on their clinical use. It serves as a complete one-stop source for undergraduate/graduate pharmacists, pharmaceutical science students, and for those in the pharmaceutical industry. The Fifth Edition completely updates the previous edition, and also includes additional coverage on the newer approaches such as oligonucleotides, siRNA, gene therapy and nanotech and enzyme replacement therapy.

This textbook, aimed at advanced undergraduate and graduate students, introduces the basic knowledge required for nanomedicine and nanotechnology, and emphasizes how the combined use of chemistry and light with nanoparticles can serve as treatments and therapies for cancer.

This handbook is unique in its comprehensive coverage of the subject and focus on practical applications in diverse fields. It includes methods for sample preparation, the role of certified reference materials, calibration methods and statistical evaluation of the results. Problems concerning inorganic and bioinorganic speciation analysis, as well as special aspects such as trace analysis of noble metals, radionuclides and volatile organic compounds are also discussed.

The objective of this third edition is to consolidate within a single text the most current knowledge, practical methods, and regulatory considerations pertaining to formulations development with poorly water-soluble molecules. A pharmaceutical scientist’s approach toward solubility enhancement of a poorly water-soluble molecule typically includes detailed characterization of the compound’s physiochemical properties, solid-state modifications, advanced formulation design, non-conventional process technologies, advanced analytical characterization, and specialized product performance analysis techniques. The scientist must also be aware of the unique regulatory considerations pertaining to the non-conventional approaches often utilized for poorly water-soluble drugs.

The objective of this third edition is to consolidate within a single text the most current knowledge, practical methods, and regulatory considerations pertaining to formulations development with poorly water-soluble molecules. A pharmaceutical scientist’s approach toward solubility enhancement of a poorly water-soluble molecule typically includes detailed characterization of the compound’s physiochemical properties, solid-state modifications, advanced formulation design, non-conventional process technologies, advanced analytical characterization, and specialized product performance analysis techniques. The scientist must also be aware of the unique regulatory considerations pertaining to the non-conventional approaches often utilized for poorly water-soluble drugs.

The development of new CNS drugs is notoriously difficult. Drugs must reach CNS target sites for action and these sites are protected by a number of barriers, the most important being the blood–brain barrier (BBB). Many factors are therefore critical to consider for CNS drug delivery, e.g.

Humans have numerous microorganisms residing in the body, especially in the gut, far exceeding the human body's normal mammalian cells. Recent research links the gut microbiome, the population of microorganisms living in the gastrointestinal tract, with brain diseases. This volume explores the concept and possibility of its extension to manage a galaxy of CNS diseases, including Parkinson's, Alzheimer's, Autism spectrum disorders, depression, insomnia, and chronic fatigue syndrome. This volume elaborates about communication channels between gut and brain via the vagus nerve, short-chain fatty acids including omega acids, and other inflammasomes.

Risikoanalysen sind Methoden des Qualitätsrisikomanagements und nehmen eine wichtige Stellung ein. Der pharmazeutische Prozess umfasst verschiedene Bereiche, u.a. die Produktentwicklung, das regelkonforme Betreiben von Produktionsanlagen, die Beschaffung von Ausgangsmaterialien, die Fertigung von Produktchargen, die Prüfung in der Qualitätskontrolle, die Überwachung der Einhaltung aller Regularien durch die Qualitätssicherung, die Dokumentation und die Bewertung von Auffälligkeiten oder Abweichungen bis hin zur Lagerung und dem Vertrieb der Produkte.